Subsequently, Vredevoogd and colleagues combined these earlier observations to show that increasing sensitivity of tumor cells to TNF killing by removal of TRAF2 enhanced the therapeutic effect of ICI drugs. This evidence concerns the gene TNF and neoplasm.